Informazione:
Errore:
ID
22125
Descrizione
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00441168
collegamento
https://clinicaltrials.gov/show/NCT00441168
Keywords
versioni (1)
- 20/05/17 20/05/17 -
Caricato su
20 maggio 2017
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Eligibility Multiple Myeloma NCT00441168
Eligibility Multiple Myeloma NCT00441168
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT00441168
- StudyEvent: Eligibility
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
refractory multiple myeloma, vincristine, adriamycin, dexamethasone
Item
relapsed or refractory multiple myeloma following 1 previous line of therapy and, is scheduled by the investigator to be treated with vincristine, adriamycin and dexamethasone standard therapy
boolean
C0026764 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0042679 (UMLS CUI [1,3])
C0085752 (UMLS CUI [1,4])
C0011777 (UMLS CUI [1,5])
C0205269 (UMLS CUI [1,2])
C0042679 (UMLS CUI [1,3])
C0085752 (UMLS CUI [1,4])
C0011777 (UMLS CUI [1,5])
secretory multiple myeloma
Item
measurable secretory multiple myeloma based on defined criteria
boolean
C0026764 (UMLS CUI [1,1])
C1327616 (UMLS CUI [1,2])
C1327616 (UMLS CUI [1,2])
karnofsky performance status
Item
karnofsky performance status of >or = 60%
boolean
C0206065 (UMLS CUI [1])
laboratory requirement
Item
fulfils defined laboratory requirements within 14 days before baseline
boolean
C0022877 (UMLS CUI [1])
postmenopausal, contraception
Item
if female, the patient is either postmenopausal or surgically sterilised or willing to use an acceptable method of birth control for defined period of time
boolean
C0232970 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
contraception
Item
if male, the patient agrees to use an acceptable barrier method for contraception for a defined period of time.
boolean
C0700589 (UMLS CUI [1])
multiple myeloma previous therapy
Item
more than one previous line of therapy for multiple myeloma
boolean
C0026764 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,2])
bortezomib
Item
use of bortezomib in the previous line of therapy and/or received bortezomib in a previous trial
boolean
C1176309 (UMLS CUI [1])
hypersensitivity to bortezomib, boron, mannitol
Item
known allergy or hypersensitivity to bortezomib, boron or mannitol
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C0006030 (UMLS CUI [1,3])
C0024730 (UMLS CUI [1,4])
C1176309 (UMLS CUI [1,2])
C0006030 (UMLS CUI [1,3])
C0024730 (UMLS CUI [1,4])
peripheral neuropathy, neuropathic pain
Item
peripheral neuropathy or neuropathic pain of grade 2 or higher
boolean
C0031117 (UMLS CUI [1])
C0458960 (UMLS CUI [2])
C0458960 (UMLS CUI [2])
heart diseases
Item
myocardial infarction within 6 months of enrollment or had new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
boolean
C0018799 (UMLS CUI [1])